For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230106:nRSF9205La&default-theme=true
RNS Number : 9205L HeiQ PLC 06 January 2023
06 January 2023
HeiQ Plc
("HeiQ" or "the Company")
Director / PDMR Dealing
HeiQ Plc (LSE: HEIQ), a leading company in materials innovation and hygiene
technologies, has been notified that on 5 January 2023, Carlo Centonze, Chief
Executive Officer of the Company, purchased 261,171 ordinary shares in the
Company ("Ordinary Shares") at a price of 28 pence per share.
Following the purchase, Mr. Centonze holds an interest in 14,448,317 Ordinary
Shares, including 5,186,237 Ordinary Shares held by Cortegrande AG, a company
wholly owned by Mr. Centonze. The total interest held by Mr. Centonze
represents approximately 10.31 per cent. of the Company's issued ordinary
share capital.
This announcement, including the notification below, is made in accordance
with the requirements of the UK Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Mr. Carlo Centonze
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name HeiQ plc
b) LEI 213800IGT65IMJDO4S03
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 30 pence each
Identification code
GB00BN2CJ299
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
28.0 pence 261,171
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 5 January 2023
f) Place of the transaction London Stock Exchange, Main Market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
5 January 2023
f)
Place of the transaction
London Stock Exchange, Main Market
For further information, please contact:
HeiQ Plc +41 56 250 68 50
Carlo Centonze (CEO)
Cenkos Securities plc (Joint Broker) +44 (0) 207 397 8900
Stephen Keys / Callum Davidson
SEC Newgate (Media Enquiries) +44 (0) 20 3757 6882
Elisabeth Cowell / Axaule Shukanayeva / Molly Gretton HeiQ@s (mailto:HeiQ@secnewgate.co.uk) ecnewgate (mailto:HeiQ@secnewgate.co.uk)
.co.uk (mailto:HeiQ@secnewgate.co.uk)
About HeiQ
HeiQ is focused on improving the lives of billions of people world-wide by
innovating the materials people use every day. HeiQ has strong IP which is at
the forefront of global technology in the $10 billion antimicrobial fabrics
market, $24 billion textile chemicals market, the $50 billion probiotics
market and the $150 billion man-made fibers market. It has also moved into the
medical device, healthcare and hygiene coatings markets, to help make
hospitals and healthcare environments more hygienic. HeiQ aims to deliver
growth for its shareholders through a combination of increased sales of its
core products and by entering additional lucrative markets through disruptive
innovations and M&A.
HeiQ has created some of the most effective, durable and high-performance
technologies in the market today, which cool, warm, dry, repel, purify, and
destroy viruses. Since 2005, HeiQ has developed over 200 technologies in
partnership with 300 major brands and it has a significant R&D pipeline
containing over 50 projects. The Company has won multiple awards and gained a
strong reputation for the ESG & sustainable downstream effect of its
innovations. HeiQ is the only company to have won the Swiss Technology award
twice. It has also won the Swiss Environmental award with an innovation that
saves energy and water consumption during the textile manufacturing process.
Led by an experienced leadership team, HeiQ researches new solutions for
partners, delivers scaled up manufacturing from its sites across the world and
helps partners market the product to end consumers - aiming for lab to
consumer in months.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHNKABNABKKFDK